Teva Canada has issued a recall for specific Teva-Pregabalin 150 mg capsules due to potential contamination with sertraline, as uncovered during routine testing. The affected lots, with serial numbers 100070495 and 100068913, were initially distributed in Canada in September 2025 and are set to expire on July 31, 2027.

Individuals with a hypersensitivity or allergic reaction to sertraline may experience adverse effects, including severe allergic reactions such as anaphylaxis, even at minimal exposure levels, as per a recall advisory from Health Canada. Anaphylactic reactions have the potential to be life-threatening. Health Canada advises individuals in possession of products from the mentioned lots to promptly return them to a pharmacy.

Pregabalin, primarily prescribed for managing nerve damage-induced pain, and sertraline, utilized for alleviating symptoms associated with depression, obsessive-compulsive disorder, and panic disorders, are the medications involved in this recall. Teva Canada, headquartered in Toronto, emphasized in its recall notice that this action is a precautionary measure.